AmMax Bio
Phase 2AmMax has built a robust oncology pipeline by leveraging its translational expertise with its lead program, AMB-066, supported by compelling preclinical data and a well-established safety profile across 6 completed clinical trials.
Founded
2019
Focus
AntibodiesBiologics
About
AmMax has built a robust oncology pipeline by leveraging its translational expertise with its lead program, AMB-066, supported by compelling preclinical data and a well-established safety profile across 6 completed clinical trials.
Funding History
1Total raised: $25M
Series A$25MMorningside VenturesJun 15, 2022
Company Info
TypePrivate
Founded2019
LocationSan Francisco, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile